Foundayo Tracker App
Track Your Foundayo (Orforglipron) Protocol
Foundayo (orforglipron) is Eli Lilly's oral GLP-1 pill with up to 14.7% weight loss in Phase 2 trials. Shotlee is the free app to track your complete Foundayo protocol — daily doses, side effects, weight, and labs.
What Is Foundayo?
Foundayo (orforglipron) is Eli Lilly's oral non-peptide GLP-1 receptor agonist — a once-daily weight loss pill that doesn't require injections or fasting. Phase 3 ATTAIN trials have shown meaningful weight loss, and FDA submission is underway.
Shotlee tracks every aspect of your Foundayo protocol: daily pill intake, doses, side effects, weight changes, measurements, and lab results. Whether you're starting Foundayo or optimizing your dose, clean data helps you and your prescriber make better decisions.
What to Track in Shotlee
Build a complete Foundayo protocol record from day one.
How to Track Your Foundayo Protocol
Foundayo Key Facts
Protocol FAQs
Foundayo is the brand name for orforglipron, a once-daily oral non-peptide GLP-1 receptor agonist from Eli Lilly. It's a pill — no injections, no fasting requirements. Phase 3 trials show meaningful weight loss.
Yes. Foundayo is the brand name and orforglipron is the generic (drug) name for the same medication — Eli Lilly's once-daily oral GLP-1 pill. If you see either name, it refers to the same product.
Foundayo (orforglipron) is a once-daily oral tablet. Unlike older oral GLP-1s, it does not require fasting or strict water timing, and unlike most GLP-1 drugs it needs no injection — a key reason interest in it is rising so fast.
Final pricing and formulary coverage depend on approval status, your insurer, and any manufacturer savings program, so out-of-pocket cost varies. Log your refills and what you actually pay in Shotlee to track your real monthly cost over time.
Open Shotlee, select Foundayo (orforglipron), and log your daily pill dose. Track weight, side effects, and labs alongside. Daily reminders keep you consistent.
Yes — Foundayo tracking is completely free forever. Premium AI features are available optionally.
Open the Shotlee app, navigate to the dose logging screen, select Foundayo as your medication, and enter the dose amount and time. Shotlee stores all entries with timestamps and lets you view your complete dose history, adherence rate, and missed dose alerts.
Track gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation), appetite changes, energy levels, and any unusual symptoms. Log these daily in Shotlee so you can share accurate trend data with your healthcare provider.
Most patients notice appetite changes within the first one to two weeks. Measurable weight loss typically becomes apparent by weeks four to eight, depending on the dose titration schedule. Track your weekly weight in Shotlee to visualize your personal response curve.
Track Your Foundayo Protocol in Shotlee
Free dose logs, side effect tracking, weight trends, and lab results — all in one app.
📚References & sources
Latest on Foundayo
Eli Lilly's Foundayo: A New Daily Pill Outperforming Oral Semaglutide
A groundbreaking Phase 3 trial reveals that Eli Lilly's new daily oral medication, orforglipron (Foundayo), demonstrates superior efficacy in lowering blood sugar and promoting weight loss compared to existing oral semaglutide treatments for individuals with Type 2 diabetes. This development marks a significant step forward in non-injectable peptide therapies for metabolic health.
6 min read
Eli Lilly's $4.5 Billion Expansion: Fueling the Future of Weight Loss & Health
Eli Lilly's monumental $4.5 billion investment in its Indiana facilities signals a significant ramp-up in production for groundbreaking GLP-1 agonists like Mounjaro and Zepbound, alongside future weight loss and cardiometabolic disease treatments. This expansion is poised to meet surging global demand and solidify Lilly's position at the forefront of pharmaceutical innovation.
6 min read
Eli Lilly's Oral GLP-1: A Strong Start Amidst Weight Loss Drug Hype
Eli Lilly's groundbreaking oral GLP-1, Foundayo, is demonstrating a promising launch, exceeding initial expectations and hinting at a significant expansion of the weight loss and diabetes management market. Discover the latest insights and what it means for patients and the industry.
7 min read